Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Beijing’s Therorna Raises $42 Million for circRNA Vaccines/Therapies (Including COVID)

publication date: Jun 21, 2022

Therorna, a Beijing biotech company developing novel vaccines and therapies based on circular RNA (circRNA) technology, closed a $42 million Series A financing round. Founded in 2021, the company uses its technology to create novel prophylactic and therapeutic drugs, including a broad-spectrum circRNA vaccine for COVID-19. Earlier this year, Professor Wensheng Wei, the scientific founder of Therorna, together with his team, published promising preclinical data on a COVID-19 circRNA vaccine in the journal Cell. The A round was co-led by a well-known industrial investment firm and MSA Capital. More details....

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022